Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05817097
Other study ID # AJOUIRB-EX-2023-089
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 2023
Est. completion date December 30, 2024

Study information

Verified date July 2023
Source Ajou University School of Medicine
Contact SooJung Kim
Phone 82-31-219-6773
Email 438104@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to compare severity and mortality rates of acute cerebral infarction(requiring thrombolysis or endovascular recanalization) depending on the type of oral antidiabetic drug taken before the onset of cerebral infarction. Researchers will compare the group that used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction and the group that did not use them to see the effect of DPP-4 inhibitors in reducing severity of cerebral infarction.


Description:

This is a retrospective study to see the effects of reducing the severity of cerebral infarction(requiring thrombolysis or endovascular recanalization) of DPP-4 inhibitors by comparing the survival rate after acute cerebral infarction hospitalization, discharge rate to home, and medical cost. A. Severity of cerebral infarction and poor prognosis is mainly associated with hyperglycemia caused by diabetes, which increases the Infarction volume and hemorrhagic trasformation. B. However, the effect of loergin blood glucose on reducing the Infarction volume and improving prognosis of cerebral infarction has not been proven. C. Preclinical studies have demonstrated a anti-stroke effect that reduces the Infarction volume using certain anti-diabetic drugs. D. Therefore, there is a possibility that certain anti-diabetic drugs may reduce the severity of cerebral infarction as a class effect in addition to the effect of blood sugar control. E. This is particularly likely to exist in the DPP-4 inhibitor family identified through preclinical studies.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 22119
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Patients with acute cerebral infarction who underwent thrombolysis or endovascular recanalization in Korea between 2014 and 2021 - Those who have been previously diagnosed with diabetes and are taking oral anti-diabetic drugs - Adult (over 19 years of age) - The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug. Exclusion Criteria: - Patients taking insulin to control diabetes

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dipeptidyl peptidase-4 inhibitor
The definition of antidiabetic drug use is defined as a case in which an antidiabetic drug was prescribed for at least 2 months before stroke and the duration of treatment for stroke coincided with the prescribed duration of the drug.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Ajou University School of Medicine Dong-A ST Co., Ltd.

References & Publications (7)

Darsalia V, Ortsater H, Olverling A, Darlof E, Wolbert P, Nystrom T, Klein T, Sjoholm A, Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013 Apr;62(4):1289-96. — View Citation

Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, Fansler A, Van de Bruinhorst K, Janis S, Durkalski-Mauldin VL; Neurological Emergencies Treatment Trials Network and the SHINE Trial Investigators. Intensive vs Standard Treatment of Hyperglyce — View Citation

Kim JY, Kang K, Kang J, Koo J, Kim DH, Kim BJ, Kim WJ, Kim EG, Kim JG, Kim JM, Kim JT, Kim C, Nah HW, Park KY, Park MS, Park JM, Park JH, Park TH, Park HK, Seo WK, Seo JH, Song TJ, Ahn SH, Oh MS, Oh HG, Yu S, Lee KJ, Lee KB, Lee K, Lee SH, Lee SJ, Jang MU — View Citation

Lee SJ, Yoon BS, Hong JM, Joe EH, Lee JS. Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat. Exp Neurol. 2022 Feb;348:113922. doi: 10.1016/j.expneurol.2021.113922. Epub 2021 Nov 12. — View Citation

Park SH, Jeong HE, Oh IS, Hong SM, Yu SH, Lee CB, Shin JY. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study. Diabetes Obes Metab. 2021 Jun;23(6):1232-1241. doi: 10.1111/dom.14330. Epub 2021 Feb 10. — View Citation

Shim DH, Kim Y, Roh J, Kang J, Park KP, Cha JK, Baik SK, Kim Y. Hospital Volume Threshold Associated with Higher Survival after Endovascular Recanalization Therapy for Acute Ischemic Stroke. J Stroke. 2020 Jan;22(1):141-149. doi: 10.5853/jos.2019.00955. E — View Citation

Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019 Apr;150:8-16. doi — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1-year survival rate The survival rates of the DPP-4 inhibitor group and the non-use group are compared 1 year after the onset of severe stroke. Check the data one year after the onset of stroke.
Primary 90-day survival rate The survival rates of the DPP-4 inhibitor group and the non-use group are compared 90-day after the onset of severe stroke. Check the data 90-day after the onset of stroke.
Primary re-hospitalization The re-hospitalization rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke. 1 year after discharge the stroke treatment.
Primary frequency of cerebral hemorrhage The frequency of cerebral hemorrhage rates of the DPP-4 inhibitor group and the non-use group are compared after the onset of severe stroke. Hospitalization period and 1 year after discharge the stroke treatment.
Primary Rate of Intensive care unit treatment The Intensive care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared. Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Primary Duration of Intensive care unit The duration of Intensive care unit of the DPP-4 inhibitor group and the non-use group are compared. Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Primary Rate of Stroke care unit treatment The Stroke care unit treatment rate of the DPP-4 inhibitor group and the non-use group are compared. Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Primary Duration of Stroke care unit The duration of Stroke care unit of the DPP-4 inhibitor group and the non-use group are compared. Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Primary tracheal intubation period The tracheal intubation period of the DPP-4 inhibitor group and the non-use group are compared. Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Primary total hospitalization days The total hospitalization days of the DPP-4 inhibitor group and the non-use group are compared. Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Primary medical expenses incurred at the time of hospitalization The medical expenses incurred at the time of hospitalization of the DPP-4 inhibitor group and the non-use group are compared. Hospitalization period is expected to be up to three months. It is not possible to accurately estimate the period of hospitalization due to severe stroke.
Secondary Home discharge rate The Home discharge rate of the DPP-4 inhibitor group and the non-use group are compared. At the end of discharge from stroke treatment.
Secondary medical expenses after discharge from hospital The medical expenses after discharge from hospital of the DPP-4 inhibitor group and the non-use group are compared. 1 year after discharge the stroke treatment.
See also
  Status Clinical Trial Phase
Withdrawn NCT02551003 - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy Phase 1/Phase 2
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT00684515 - Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Terminated NCT01684462 - The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00386191 - Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment Phase 4
Completed NCT00004734 - Vitamin Therapy for Prevention of Stroke Phase 3
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Completed NCT02248233 - Nimodipine for Treating Acute Massive Cerebral Infarction Phase 4
Completed NCT02963545 - TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke N/A
Completed NCT02511249 - Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke N/A
Completed NCT02101606 - Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke Phase 2
Completed NCT01500421 - Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund) Phase 2
Completed NCT00829361 - Stroke Telemedicine for Arizona Rural Residents Trial N/A
Recruiting NCT01003470 - Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study Phase 2
Terminated NCT00331890 - ICTUS Study: International Citicoline Trial on Acute Stroke Phase 3
Not yet recruiting NCT04696523 - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT03741400 - Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke N/A